Indefinite Delivery Contract 75N93021D00031

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded an Indefinite Delivery Contract to Lovelace Biomedical Research Institute on September 1, 2021 with a potential value of $545,452,906. Under the terms of the contract, Lovelace Biomedical Research Institute will provide a broad range of services to support biomedical research conducted by NIAID, including clinical trials, manufacturing and controls, nonclinical animal studies, analytics, bioinformatics, computational biology, biostatistics, storage, regulatory and quality assurance services, and basic and mechanistic research. Two associated delivery orders were issued against the contract to date. The first, awarded September 26, 2022 for $716,374, is for a Good Laboratory Practice repeat dose toxicology study of BPL-24910 to be performed in Rockville, Maryland over 14 months. The second, awarded September 1, 2021 for $2,000, provides comprehensive and rapid response services in Bethesda, Maryland to support NIAID's research programs for one year.

The originating pre-solicitation notice sought proposals for an Indefinite Delivery Indefinite Quantity contract to provide capacity and capability for services supporting NIAID's mission of conducting and advancing research on infectious, immunologic, and allergic diseases. The solicitation specified support for NIAID's Division of Clinical Research, Division of Intramural Research, and Vaccine Research Center, covering areas such as clinical trials, CMC activities, nonclinical animal studies, analytics, and basic research. The contract was partially set aside for small businesses and carries an ordering period from September 2021 through August 2028 to rapidly and efficiently address NIAID's research needs.